why choose us

First received: July 24, 2023

Clinical Trial: Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: T Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma

Brief Summary: Single- arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).

Read more